Previous 10 | Next 10 |
PTC Therapeutics Opens Applications for the Annual STRIVE Awards Program and Introduces a New Award Category - New category targets programs that support the transition from adolescence to adulthood - - Proposal submissions for 2021 STRIVE Awards are due March 15, 2021 - ...
PTC Therapeutics (PTCT) announces 2021 potential milestones and 2020 preliminary results.Total net product revenue for FY 2020 is expected ~$333M.Q4 and FY20 Translarna revenue of $69M and ~192M, resp.Q4 and FY20 Emflaza revenue of $37M and ~$139M, resp.The company expects to report...
PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference - ~$333 million prelimi...
PTC Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH PLAINFIELD, N.J. , Jan. 4, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the 39th...
PTC Therapeutics to Host Translarna™ Deep Dive Webinar SOUTH PLAINFIELD, N.J. , Dec. 9, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing Translarna on Tuesday, December 15 at 12:00 noon ET...
PTC Therapeutics ([[PTCT]] -1.5%) announces the regulatory nod in Russia for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy ((DMD)) in patients at least two years old.The company has experienced headwinds getting the product approved in major markets. The FDA is ...
PTC Announces Translarna™ Approval in Russia for the Treatment of Duchenne Muscular Dystrophy SOUTH PLAINFIELD, N.J. , Dec. 4, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Translarna™ (ataluren) has been granted marke...
PTC Therapeutics ([[PTCT]] -1.6%) has initiated Phase 3 MOVE-FA study evaluating vatiquinone (PTC743) in children and young adults with Friedreich ataxia, a genetic, neuro-degenerative movement disorder, typically diagnosed in childhood or adolescence.Vatiquinone has been granted FDA Orp...
PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia - Third trial initiated in 2020 from compounds identified from PTC's Bio-e platform - PR Newswire SOUTH PLAINFIELD, N.J., Nov. 30, 2020 SOUTH PLA...
Centogene N.V. (CNTG) has expanded its partnership with PTC Therapeutics (PTCT). The companies will work together to provide genetic testing and 3-O-Methyldopa (3-OMD) biomarker analytics to help identify patients with Aromatic L-amino Acid Decarboxylase ((AADC)) deficiency, a rare genet...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....